NYSE:JNJ 27 June 2025 - 22 August 2025

The first half of 2025 has seen biotechnology and health technology sectors accelerate on multiple fronts, from groundbreaking scientific advances to robust deal-making. Industry optimism is high – a Deloitte survey of 150 life science executives found 75% believe 2025 will be a strong year, citing anticipated revenue growth and rapid innovation genengnews.com. This optimism is translating into action, with emerging technologies like gene editing, precision medicine, digital health, and AI reaching new milestones. Meanwhile, global market projections remain bullish: for example, the AI in healthcare market is projected to grow about 10-fold from ~$15 billion in 2024 to over $164 billion by 2030 globenewswire.com, and the digital health market is expected to soar past $1 trillion by the early 2030s precedenceresearch.com. Biotech companies are capitalizing on scientific breakthroughs and improving financial conditions. Venture capital funding is rebounding after a post-pandemic dip – in Q1 2025, healthtech startups raised $3.5 billion across 185 deals, even minting five new unicorns linkedin.com linkedin.com. At the same time, large corporations and investors are pursuing strategic acquisitions and partnerships to gain cutting-edge capabilities. In short, 2025’s mid-year snapshot reveals a dynamic landscape: gene and cell therapies are reaching patients, AI is becoming embedded across